Literature DB >> 30642741

An extranodal histopathological analysis of idiopathic multicentric Castleman disease with and without TAFRO syndrome.

Nozomu Kurose1, Ken-Ichi Mizutani2, Motona Kumagai2, Akihiro Shioya2, Xin Guo2, Satoko Nakada2, Shino Fujimoto3, Hiroshi Kawabata3, Yasufumi Masaki3, Kazue Takai4, Sadao Aoki5, Masaru Kojima6, Shigeo Nakamura7, Masatoshi Kida8, Sohsuke Yamada2.   

Abstract

Thrombocytopenia, anasarca, fever, renal failure or reticulin fibrosis, and organomegaly (TAFRO) syndrome, a poor prognostic clinical condition showing similar histopathological findings to idiopathic multicentric Castleman disease (iMCD), has been reported in Japan. In our previous report, a clinicopathological analysis was performed on 70 nodal cases of iMCD with/without TAFRO. iMCD is classified into three types based on histopathology: (i) plasmacytic (PC), (ii) mixed, and (iii) hypervascular (hyperV). In this report, extranodal histopathological changes of iMCD with/without TAFRO were analyzed. Regarding the kidney pathology, we observed the proliferation of mesangial cells with positive staining of interleukin-6 (IL-6), consistent with membranoproliferative glomerulonephritis, in two cases of iMCD with TAFRO. The number of megakaryocytes per high-powered fields was not significantly different between iMCD cases with and without TAFRO. In conclusion, extranodal lesions of iMCD with/without TAFRO showed various interesting histopathological findings. These lesions may therefore be related to the clinical condition of TAFRO. Obtaining further knowledge about TAFRO will require the observation of nodal as well as extranodal lesions.
Copyright © 2018 The Authors. Published by Elsevier GmbH.. All rights reserved.

Entities:  

Keywords:  Extranodal lesion; Idiopathic multicentric Castleman disease; Membranoproliferative glomerulonephritis; Syndrome; TAFRO

Mesh:

Substances:

Year:  2018        PMID: 30642741     DOI: 10.1016/j.prp.2018.12.025

Source DB:  PubMed          Journal:  Pathol Res Pract        ISSN: 0344-0338            Impact factor:   3.250


  4 in total

1.  Pathological findings of progressive renal involvement in a patient with TAFRO syndrome.

Authors:  Hirotaka Saito; Kenichi Tanaka; Momoko Fujiwara; Tsuyoshi Iwasaki; Tokutaro Numata; Akira Oda; Makoto Kanno; Mizuko Tanaka; Masaaki Eiro; Mamoru Satoh; Junichiro James Kazama
Journal:  CEN Case Rep       Date:  2019-05-10

Review 2.  Germline Predisposition to Hematolymphoid Neoplasia.

Authors:  Olga K Weinberg; Frank Kuo; Katherine R Calvo
Journal:  Am J Clin Pathol       Date:  2019-08-01       Impact factor: 2.493

Review 3.  Renal Pathologic Findings in TAFRO Syndrome: Is There a Continuum Between Thrombotic Microangiopathy and Membranoproliferative Glomerulonephritis? A Case Report and Literature Review.

Authors:  Amélie Leurs; Viviane Gnemmi; Arnaud Lionet; Loïc Renaud; Jean-Baptiste Gibier; Marie-Christine Copin; Eric Hachulla; Pierre-Yves Hatron; David Launay; David Fajgenbaum; Louis Terriou
Journal:  Front Immunol       Date:  2019-06-28       Impact factor: 8.786

4.  TAFRO Syndrome and Elusive Diagnosis of Idiopathic Multicentric Castleman Disease Treated with Empiric Anti-Interleukin-6 Therapy.

Authors:  Corinne Williams; Alexis Phillips; Vikram Aggarwal; Liron Barnea Slonim; David C Fajgenbaum; Reem Karmali
Journal:  Case Rep Oncol       Date:  2021-09-21
  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.